A promising new treatment for extensively drug-resistant (XDR) tuberculosis (TB) that was tested in SA has been submitted to US regulators, taking its developers a step closer to providing patients with far better odds of defeating the disease. XDR-TB is a strain of the disease that is resistant to a wide range of antibiotics, and consequently difficult to treat. Although the outlook for patients in SA has improved with the recent introduction of Johnson & Johnson’s Bedaquiline, the cure rate is still only about 60%. The new treatment includes the novel chemical entity pretomanid, developed by the TB Alliance, with generic linezolid, and Bedaquiline. This “BPaL” regimen cures 89% of patients, according to the interim results of the Nix-TB trial, presented at the Union World Conference on Lung Health in 2018. “It is a watershed treatment,” the principal investigator of the Nix-TB trial, Francesca Conradie, told Business Day on Wednesday. The trial results have been submitted to a pee...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, Morningstar financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00.